Lupus Nephritis Market - Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning / Landscape Review & Global Market Size Forecast to 2032
Overview
Lupus Nephritis Market was worth USD 2.02 Billion in 2023, is estimated to grow at a CAGR of 6.8% in the forecasted period. The forecasted revenue hints at a growth of around 3.21 billion USD by 2030
Various treatments like corticosteroids and other drugs can supress the Lupus Nephritis disease to some extent. The Lupus Nephritis is a type of kidney disease that is caused by systemic lupus erythematosus (SLE), an autoimmune disease. Thus, the market shows huge opportunities especially when the cases are increasing in millions. Out of every 10-kidney suffering patient, 5 are suffering from lupus, which aggravates the importance of the lupus nephritis industry.
The market is dominated by North America and Europe due to increased patients suffering from SLE, while Asia Pacific companies have nearly equal share because of high population thus creating high demands for the treatment. Increasing number of clinical trials and the launch of new drugs will also augment the growth of the global lupus nephritis market. Thus, the market has good scope for new entrants as well as established players to enter the market. Also, a CAGR of 6.8% is evident because of technological advancements, recent awareness campaigns and availability of drugs.
To know about the Research Methodology :- Request Free Sample Report
Market Drivers in Lupus Nephritis Market
With increasing prevalence of the disease, the need for treatment also increases. Thus, opening new domains for companies to invest. High investments in R&D and huge development in the technology have also helped the lupus nephritis market grow. Nearly 5 million people have been affected and the numbers are increasing especially in US and Southern Europe. Lupus Nephritis is a common complication which requires effective treatments. Global Awareness has been playing an important role as more people are recorded, more they can be treated.
Many big companies are investing in their research, which can lead us to new markets of drugs. AstraZeneca's working on Saphnelo which can reduce the symptoms in an adult body. Thus, new treatments will be crucial to determine the future prospect of the market. Governments are investing in healthcare infrastructure and programs to improve the diagnosis and treatment of lupus nephritis, which is driving the growth of the market. So, the key drivers are technological advancement which would mean new treatments like low-dose intravenous cyclophosphamide treatment for patients with proliferative lupus nephritis.
Challenges in Lupus Nephritis market
To identify the right patient and at the right time is quite challenging considering it is an autoimmune disease and may overlap with other diseases. But awareness campaigns have made sure that patients are aware of the repercussions of delaying such infections. The current treatments for lupus nephritis, such as immunosuppressant drugs and corticosteroids, can have significant side effects. These side effects can be fatal or non – fatal, but are surely a challenge for the Lupus Nephritis market. These can include an increased risk of infections, weight gain, osteoporosis, and mood changes. Lupus nephritis is a long-term disease especially its treatment often takes months to complete, which creates a challenge in monitoring.
Lupus Nephritis Market Trend
In terms of treatment options, there are several drugs available for lupus nephritis, including
corticosteroids, immunosuppressants, and biologics. However, there is still a need for more effective and targeted therapies that can improve the current standards and make the process at ease. The lupus nephritis market is also seeing an increasing number of clinical trials focused on developing new therapies. These trials are exploring novel drug candidates, such as monoclonal antibodies and small molecules, which could potentially provide better treatment options for patients with lupus nephritis. In addition, there is a growing interest in precision medicine approaches for lupus nephritis, which aim to identify individual patient characteristics to better tailor treatments to their specific needs. This could potentially improve patient outcomes and reduce healthcare costs. Overall, the lupus nephritis market is expected to continue growing as research and development efforts continue to advance and as healthcare systems around the world continue to improve.
Lupus Nephritis Market Segmentation
Lupus Nephritis Market based on Drugs Class
Immunosuppressive drugs are used in severe cases especially when immune system fails to activate upon an infection. Corticosteroids are often used during lupus nephritis treatment as it these drugs are effective at reducing inflammation, but they also have significant side effects, such as weight gain, bone loss. Belimumab is an emerging drug class which has huge potential in future. Belimumab is a monoclonal antibody that inhibits B cell activation
Lupus Nephritis Market based Route of Administration
Oral and Parenteral are two types of routes through which a drug can be transported. Oral is preferable action as its easy to clear and monitor symptoms of the patient. Parenteral id often used in severe conditions or when oral route fails to create an impact in the patient’s body. Injectable steroids may also have side effects, such as an increased risk of infection.
Lupus Nephritis Market based on End Users
Hospitals and Specialty Clinics are two end users of Lupus Nephritis market. Hospitals directly use their drugs to treat patients who visit the hospital while Speciality clinics can provide care and expertise in the diagnosis, treatment, and monitoring of this complex condition.
Lupus Nephritis Market based on Distribution Channel
Hospital Pharmacy is the main distribution channel in Lupus nephritis market. As the disease is complex and requires special attention, the treatment for it is also placed specially in hospitals and speciality clinics which makes sure that the drugs are used for right purposes. Retail pharmacy is also another channel for distribution where general medicine to manage symptoms are provided based on prescriptions. Online Pharmacy is not a huge channel, as very less percentage of sale happens online.
Lupus Nephritis Market Based on Region
Regional Insights
Global
Globally, the Lupus Nephritis market is huge and is bound to increase with technological advancements and high – tech treatment facilities. The global market has many players from various regions having some hold over the market share, where North America is the dominant player. North American market for Lupus Nephritis industry is huge, because US is the place having most infected people. Also, US possess good facilities to store and develop drugs to cure the treatment.
Lupus Nephritis Market North America
The US is one of the leading countries in terms of revenue and market share of the Lupus Nephritis industry. The US has well-established facilities with adequate advancement in technologies to work on the Lupus Nephritis. While Canada is falling behind the US, it has taken significant measures to replicate the success of its neighbour. Canada is also home to a growing number of research institutions and biotechnology companies that are actively involved in the Lupus Nephritis research which they are leveraging to increase their market share. Many active cases have been detected in Canada and thus the Lupus Nephritis market is showing moderate growth. Mexico is also emerging market for various companies and is gaining higher percentage of Lupus Nephritis market year on year.
Lupus Nephritis Market Asia Pacific
The market in Asia Pacific is significantly showing rapid growth, which is a result of a huge population and two strong countries - India and China. Increased investments in research and drug developments, rising healthcare spending, have contributed to a rapid surge of the industry in the Asia Pacific region. Both India and China have well-developed resources and techniques to enlarge their market share. Chinese government in past decade has splashed huge cash in their R&D to develop a Lupus Nephritis industry. Thus, Asia-Pacific region is an emerging market for lupus nephritis treatments, because of high unmet medical needs and a growing patient population.
Market Europe
Europe is a significant market for lupus nephritis treatments, with a high prevalence of the condition and a favourable regulatory environment for drug development and approval. The European market has been a prevalent market share holder as many cases are reported from UK and Germany. Southern Europe has recorded the most cases of infected patients and thus have a potential to increase their market share.
Market Middle East and Africa
The lupus nephritis market in the Middle East and Africa is still emerging, with a relatively low market share compared to other regions. Lack of technological efficacy has been a huge challenge. But in recent years, Middle Eastern countries have diverted their focus on research. The Lupus Nephritis is also becoming a major concern for cities in Africa and Middle East. Saudi Arabia-based Tabuk Pharmaceuticals is one such company which are working on the treatment of Lupus Nephritis
Market South America
The Lupus Nephritis Market in South America is growing steadily, Brazil and Argentina are emerging as the dominant players. Both countries have spent huge amounts of dollars to sustain this Lupus Nephritis market. But the disparities within the region and price differences in drugs, along with technological disparities has been a major concern. Thus, the market is not pre dominant as Europe, but is showing signs due to high number of registered cases and increased awareness.
Lupus Nephritis Market: Competitive Landscape
The market is highly competitive and US companies are mostly at the helm of the market share. Big companies like Merck and Co, Johnson and Johnson have been leading the market share. Nearly 60% of the market is dictated by North American companies. Asia pacific being the region with highest growth rate has showed huge signs in increasing its market share because of high population and increasing demand. Lupus nephritis market is also focused on improving patient outcomes through initiatives such as patient education and support programs, advocacy efforts, and partnerships with healthcare providers.
European companies like GSK and AstraZeneca are also at the top and considered one of the best companies in this industry. Spending from the governments have been increased which has created a huge competition in Lupus Nephritis market. Example - Aurinia is a biopharmaceutical company that is developing voclosporin, a potential treatment for lupus nephritis. The drug is currently in Phase III clinical trials and has shown promising results. There are several other companies working on similar drugs to cure the Lupus nephritis more easily without any side effect
Lupus Nephritis Market Scope: Inquire before buying
| Lupus Nephritis Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2023 | Forecast Period: | 2024-2030 |
| Historical Data: | 2018 to 2023 | Market Size in 2023: | USD 2.02 Bn. |
| Forecast Period 2024 to 2030 CAGR: | 6.8% | Market Size in 2030: | USD 3.21 Bn. |
| Segments Covered: | by Drug Class | Immunosuppressive drugs Corticosteroids Belimumab |
|
| by Distribution Channel | Hospital Pharmacy Retail Pharmacy Online Pharmacy |
||
| by Route of Administration | Oral Parenteral |
||
| by End - User | Hospitals Speciality Clinics |
||
Lupus Nephritis Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Lupus Nephritis Market, Key Players are
1. AstraZeneca - UK
2. Aurinia Pharmaceuticals - Canada
3. Biogen - USA
4. Bristol Myers Squibb - USA
5. ChemoCentryx - USA
6. Eli Lilly and Company - USA
7. GlaxoSmithKline - UK
8. Hikma Pharmaceuticals - Jordan
9. Hoffmann-La Roche - Switzerland
10. Incyte Corporation - USA
11. Johnson & Johnson - USA
12. Merck & Co. - USA
13. Novartis - Switzerland
14. Pfizer- USA
15. Regeneron Pharmaceuticals - USA
16. Sanofi - France
17. Takeda Pharmaceutical Company - Japan
18. Teva Pharmaceutical Industries - Israel
19. UCB - Belgium
20. AbbVie - USA
21. Alexion Pharmaceuticals - USA
22. Amgen - USA
23. Gilead Sciences - USA
24. Mallinckrodt Pharmaceuticals - USA
25. Vertex Pharmaceuticals – USA
FAQ
Q.1) What is the CAGR of market?
Ans: The CAGR of market is 6.8%
Q.2) Which are the leading companies in market?
Ans: Pfizer, AstraZeneca and Merck and Co are some of the leading companies in the Lupus Nephritis market
Q.3) Which area amongst the discussed do we have a huge forecast and potential in future
Ans: Asia Pacific is expected to grow exponentially and has the most potential in future due to increasing demand, high population and huge backing from the government
Q,4) Which is the leading region in market?
Ans: North America leads the market of Lupus Nephritis significantly
Q.5) What was the forecasted period of this report?
Ans: The forecast period is from 2024 – 2030